Lung Cancer Clinical Trials in Philadelphia, Pennsylvania

7 studies are recruiting for lung cancer in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Registry for People With Lung Cancer

   Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Thomas Jefferson University Hospital (Data Collection Only), Philadelphia, Pennsylvania

   Locations

   19 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06424327 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. Evaluation of the Safety and Efficacy of Abenacianine (VGT-309) to Identify Cancer in Subjects Undergoing Surgery for Cancer in the Lung

   This is a Phase 3, multi-center, randomized and intrasubject controlled study to evaluate the safety and efficacy of abenacianine for injection, a tumor-targeted, activatable fluorescent imaging agent, to identify cancer using NIR imaging in participants undergoing surgery for cancer in the lung. A…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   9 in total

   Run by

   Vergent Bioscience, Inc.

   See if you can join NCT07499674 on ClinicalTrials.gov

4. Empathic Communication Skills (ECS) Training

   Research indicates that perceived stigma within medical encounters is prevalent and problematic for lung cancer patients' well-being and quality of cancer care. Promoting empathic communication appears to be a potentially effective intervention target to help reduce patients' perceptions of stigma …

   Stage

   Not phased

   Ages

   18 to 100

   Site

   University of Pennsylvania (Data Collection Only), Philadelphia, Pennsylvania

   Locations

   12 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05456841 on ClinicalTrials.gov

5. Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES

   This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomiz…

   Stage

   Not phased

   Ages

   35 to 89

   Site

   Penn Medicine University City, Philadelphia, Pennsylvania

   Locations

   3 in total

   Run by

   Abramson Cancer Center at Penn Medicine

   See if you can join NCT05968898 on ClinicalTrials.gov

6. Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

   This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Run by

   Fox Chase Cancer Center

   See if you can join NCT05800587 on ClinicalTrials.gov

7. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

   Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

   Locations

   21 in total

   Run by

   Clasp Therapeutics, Inc.

   See if you can join NCT06778863 on ClinicalTrials.gov